Apellis Pharmaceuticals Inc
NASDAQ:APLS
| Market Cap (Intraday) | 2.43B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $18.58 |
| 50-Day MA | $18.24 |
| 200-Day MA | $25.41 |
Apellis Pharmaceuticals Inc Stock, NASDAQ:APLS
100 5th Avenue, Suite A, Waltham, Massachusetts 02451-8703
United States of America
Phone: +1.617.977.5700
Number of Employees: 710
Description
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.